Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Discourages "Negative Safety Claims" In Labels Even At The Risk Of Inconsistency

Executive Summary

FDA does not generally allow any claims in labeling that a safety issue does not exist with the product "because the evidence to support a conclusion of 'no effect' is very difficult to generate," the agency said. It's a policy that some academics say creates confusion, though.

You may also be interested in...

Playing It Safe: How FDA Handles Its Risk-Related Buzz Words

FDA is careful to exclude phrasing from labeling that might allow a product to claim a safety advantage if it is not definitively proven, but the agency is less strict about using the term "safer" outside the labeling context.

Gadavist Dosing Complexities To Be Handled With Packaging, Not REMS

Bayer's newly approved gadolinium-based contrast agent only needs half the dose of other such products. The label eschews comparative safety claims.

Bayer's MRI Contrast Agent Gadovist Could Get "Lower-Risk" Designation

But the sponsor will have to convince an FDA advisory committee that the drug's unusual dosing will not cause medication errors in a crowded class.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts